NEWS & EVENTS
Exclusive US rights acquired by CLS | March 5, 2018 (WAYNE, PA) – Cutanea Life Sciences, Inc. has acquired the exclusive US commercialization rights for Xepi™ (ozenoxacin) Cream, 1% from Medimetriks Pharmaceuticals, Inc. Xepi™ is licensed from Spanish drug maker FERRER INTERNACIONAL, S.A., who developed the patented topical impetigo treatment that was recently approved for use in the U.S. by the Food and Drug Administration.
CLEVELAND, Jan. 18, 2017 – Athersys, Inc. (NASDAQ:ATHX) announced today that through its Belgian subsidiary, ReGenesys BVBA (ReGenesys), it has entered into an agreement with a global leader in the animal health business segment to evaluate the cell therapy technology for application in a non-disclosed animal health area. Under the terms of the agreement, ReGenesys will receive an initial payment in exchange for an exclusive period to evaluate the cell therapy technology with an option to negotiate for a license for the development and commercialization of the technology for this area. Additional details were not disclosed.
October 4, 2016 – HoneyLab, the Bay of Plenty-based healthcare company, have today announced that they have entered an exploratory relationship with Procter & Gamble in the USA. HoneyLab co-founder Laurence Greig said that HoneyLab’s strength was developing novel natural products with strong evidence for their effectiveness. He said that rather than building a brand, the aim had always been to partner with companies such as Procter & Gamble. “P&G are one of the biggest consumer companies in the world and we are delighted that our scientifically strong and innovative products have caught the eye of such a prestigious company.”